Intelligent Bio Solutions Inc. (INBS)

USD 1.27

(-6.62%)

Market Cap (In USD)

5.57 Million

Revenue (In USD)

3.11 Million

Net Income (In USD)

-10.15 Million

Avg. Volume

1.77 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0-11.7
PE
-
EPS
-
Beta Value
4.724
ISIN
US36151G6008
CUSIP
-
CIK
1725430
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Harry Simeonidis
Employee Count
-
Website
https://gbs.inc
Ipo Date
2020-12-23
Details
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.